News

France 2nd in the world?
Enlarge image

StudyFrance

France 2nd in the world?

24.05.2012 - France Biotech has presented its 2011 biotech survey together with France Biotech. The results are very favorable for the country.

Paris – The data of the Life Science Panorama 2010/11 survey provided by Ernst & Young claim a leading role for French biotechnology in the world. The accounting specialist has found an impressive number of 1,359 life science companies that are active in France, ranking the country 2nd in the world in terms of the number of such companies. However, the survey gives no clear criteria for the selection of the firms included. Other studies use clearly defined and internationally comparable criteria defined by the OECD. Furthermore, Ernst & Young only surveyed only about 200 companies. 103 firms responded. On this basis, Ernst & Young calculated annual revenues of €261 million in France. In comparison, a report from biotechnologie.de conform to OECD criteria found 552 biotech companies in Germany with €2.4bn in sales. As in Europe, the amount of private equity available for biotechs dropped sharply in France between 2010 and 2011 from €460m to €277m according to Ernst & Young, while the number of start ups founded balanced the number of companies liquidated (24 versus 25). However, the lack of private money could be largely compensated by state programmes such as the FSI-PME programme.  France also expanded its product pipeline. According to the report, 320 therapeutic products were in development whilst 20 were already being marketed in 2011. On top of that, diagnostic companies sold 59 in-vitro diagnostics and 21 in-vivo diagnostics. 

According to the report, the first foreign acquisitions by French companies took place in 2011. Swedish Cellartis AB was bought by Paris-based Cellectis S.A. and SC World Inc. from Japan by Vivalis SA (Nantes). In return, two French companies were acquired by foreign enterprises, namely Novagali Pharma S.A. (Évry) by Santen Pharmaceutical Co. Ltd. (Japan) and Ipsogen SA (Marseille) by Qiagen N.V. (Netherlands). 

http://www.european-biotechnology-news.com/news/news/2012-02/french-life-sciences-ranked-2nd-in-the-world.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTECH PHARMACON (N)16.80 NOK17.07%
  • ALMIRALL (E)17.26 EUR4.61%
  • EUROFINS SCIENTIFIC (F)301.96 EUR4.16%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • DBV TECHNOLOGIES (F)67.75 EUR-7.57%
  • CO.DON (D)2.50 EUR-7.41%

TOP

  • KARO BIO (S)39.30 SEK2419.2%
  • BIOTECH PHARMACON (N)16.80 NOK78.2%
  • TRANSGENE (F)4.92 EUR75.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-42.7%
  • THROMBOGENICS (B)2.86 EUR-42.3%

TOP

  • KARO BIO (S)39.30 SEK4417.2%
  • ADOCIA (F)82.29 EUR370.5%
  • VERONA PHARMA (UK)5.00 GBP316.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-80.0%
  • BIOTEST (D)20.00 EUR-77.0%

No liability assumed, Date: 02.09.2015